Trial Profile
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2023 Results (Cut off date : March 9, 2020 , N=71 ) published in the Lancet Oncology.
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress